Rapid Whole Genome Sequencing Study (rWGS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03385876|
Recruitment Status : Enrolling by invitation
First Posted : December 29, 2017
Last Update Posted : December 23, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Genetic Diseases Genetic Syndrome||Genetic: Genomic sequencing and molecular diagnostic results, if any||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100000 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Assignment|
|Masking:||None (Open Label)|
|Official Title:||Rapid Whole Genome Sequencing (rWGS): Rapid Genomic Sequencing for Acutely Ill Patients and the Collection, Storage, Analysis, and Distribution of Biological Samples, Genomic and Clinical Data|
|Actual Study Start Date :||August 29, 2017|
|Estimated Primary Completion Date :||December 31, 2050|
|Estimated Study Completion Date :||December 31, 2050|
Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
Genetic: Genomic sequencing and molecular diagnostic results, if any
Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
- Number of samples enrolled per year [ Time Frame: Yearly through study completion estimated to be 40 years. ]Establishment of a biorepository for genomic/precision medicine use in pediatric population. This will make samples available to study rare genetic disorders, screening methods, diagnostic methods, other "omics," and bench research for possible treatments.
- Proportion of children receiving molecular diagnoses [ Time Frame: Through study completion estimated to be 40 years. ]Utilize cutting edge technologies to improve both diagnostic rates and time to diagnosis for rare genetic diseases. Symptom driven return of results and analysis of clinical utility.
- Time taken to receive molecular diagnosis [ Time Frame: From date of enrollment until the date of documented clinical laboratory diagnosis or date of death from any cause, whichever came first, assessed up to 10 years. ]
- Proportion of children in which human phenotype ontology (HPO) terms accurately predict molecular diagnosis [ Time Frame: Through study completion estimated to be 40 years. ]
- Subject's main provider's perceived clinical utility of genomic sequencing [ Time Frame: Within one month of the return of results. ]Perceived utility/benefit of sequencing based on "Clinician Assessment" scale completed by patient's providers.
- Comparing diagnostic rates between singleton and trio analysis [ Time Frame: Within 30 days of enrollment. ]Marginal increase in diagnostic yield above singleton analysis based on the number of clinically confirmed diagnoses posted in medical record following singleton and trio levels of analysis in cases when both biological parents are available.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- The Repository will be comprised of samples from symptomatic patients, individuals reported to be their (symptomatic or asymptomatic) biologic family members, and control individuals. In this context a "symptomatic patient" is characterized as a patient whose treating physician has identified phenotypic features and/or signs of illness potentially attributable to a genetic disorder (also referred to as "Affected" or "Proband"). There will be no age, gender, race, or health restrictions for this Biorepository Study. However, since this study will be performed at children's hospitals and since genetic disorders are more likely to be present in children less than 4 months of age these cases will likely be preferentially enrolled. Preference will also be given to those who are acutely ill, suspected of a genetic condition, and for whom a diagnosis may result in change of clinical management.
- Participants will be excluded if they are unwilling to consent to research.
A patient may be determined ineligible if there is a prior diagnosis that explains their clinical presentation, if other traditional clinical genetic testing is more appropriate at the time of referral, if the clinical presentation is insufficient at the time of referral to suggest a genetic etiology, if the parents are unable or unwilling to provide permission for participation, if child protective services is involved in the case unless the child's life is in immediate danger and research holds out a prospect of direct benefit that is important to the health or well-being of the child and is available only in the context of the research in which case permission will be obtained from the party legally responsible for medical decisions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03385876
|United States, California|
|Rady Children's Institute for Genomic Medicine|
|San Diego, California, United States, 92123|
|Principal Investigator:||David Dimmock, MD||Rady Pediatric Genomics & Systems Medicine Institute|
|Study Director:||Stephen Kingsmore||Rady Pediatric Genomics & Systems Medicine Institute|
|Responsible Party:||David Dimmock, MD, Medical Director, Rady Pediatric Genomics & Systems Medicine Institute|
|Other Study ID Numbers:||
rWGS Protocol #20171726
|First Posted:||December 29, 2017 Key Record Dates|
|Last Update Posted:||December 23, 2021|
|Last Verified:||December 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Genetic Diseases, Inborn